The content on this site is intended for healthcare professionals only
Dr Tomasz M. Beer from Oregon Health & Science University, Portland, USA, speaks to ecancer at the ASCO GU congress 2014. He discusses the results from the phase III PREVAIL trial showing increased survival and delayed progression of mCRPC in men. Data were presented in full for the first time at the GU Cancer symposium.
Dr Beer states that the androgen-receptor blocker enzalutamide is likely to become an important new treatment option if approved.
For more information on this study please click here.
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Enzalutamide monotherapy prolongs MFS compared to leuprolide alone in men with high-risk biochemically recurrent PC
OncoAlert round up July 28th to August 3rd, 2023
CG0070 plus pembro shows promising efficacy in NMIBC unresponsive to BCG
Pembro monotherapy for participants with BCG–unresponsive HR NMIBC shows anti-tumour activity
Intravesical IO using durvalumab shows promising results for patients with high risk NMIBC after BCG failure
Latest in PARP inhibitors and combination therapies for prostate cancer
Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC
Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC
